Mind Medicine (MindMed) Inc. Completes Acquisition of HealthMode, Inc.

March 22, 2021

Mind Medicine (MindMed) Inc. (NEO: MMED) (“MindMed”), a psychedelic medicine biotech company that discovers, develops and deploys psychedelic inspired medicines and therapies to address addiction and mental illness, has completed its acquisition of HealthMode, Inc. (“HealthMode”), a digital medicine and therapeutics start-up that uses Artificial Intelligence (AI)-enabled digital measurement to increase the precision and speed of clinical research and patient monitoring (the “Acquisition”). MindMed acquired HealthMode to help build a full stack digital mental health platform for psychedelic medicines.

In connection with the Acquisition, Dr. Daniel Karlin, Co-Founder of HealthMode, was appointed as Chief Medical Officer of MindMed and Bradford Cross, Co-Founder of HealthMode, was appointed as Chief Technology Officer of MindMed.

Wildeboer Dellelce LLP acted for MindMed with a team comprised of Perry Dellelce, Peter Volk, Joel Fraser and Katie Drury (corporate) and Katy Pitch and Marija Tasevska (tax).